1. Goeptar, A. R., Te Koppele, J. M., Lamme, E. K., Piqué, J. M., & Vermeulen, N. P. E. (1993). Cytochrome P450 2B1-mediated one-electron reduction of adriamycin: A study with rat liver microsomes and purified enzymes. Molecular Pharmacology, 44, 1267–1277.
2. Creighton, A. M., Hellmann, K., & Whitecross, S. (1969). Antitumour activity in a series of bisketopiperazines. Nature, 222, 384–385.
3. Holcenberg, J. S., Tutsch, K. D., Earhart, R. H., Ungerleider, R. S., Kamen, B. A., Pratt, C. B., Gribble, T. J., & Glaubiger, D. L. (1986). Phase I study of ICRF-187 in paediatric cancer patients and comparison of its pharmacokinetics in children and adults. Cancer Treatment Reports, 70, 703–709.
4. Decorti, G., Bartoli Klugmann, F., Mallardi, F., Klugmann, S., Benussi, B., Grill, V., & Baldini, L. (1983). Effects of ICRF 159 on adriamycin-induced cardiomyopathy in rats. Cancer Letters, 19, 77–83.
5. Perkins, W. E., Schroeder, R. L., Carrano, R. A., & Imondi, A. R. (1982). Effect of ICRF-187 on doxorubicin-induced myocardial effects in the mouse and guinea pig. British Journal of Cancer, 46, 662–667.